OVID: A Small-Cap CNS Rebuild With Real Momentum Back in the Tape
Ovid Therapeutics is trying to earn back credibility after a brutal 2024 drawdown, but the setup into early 2026 is cleaner than most: liquid balance-sheet ratios, rising short interest that can fuel upside, and bullish near-term technical momentum. With the stock at $1.74 and still below the $2.01 52-week high, the trade is a mid-term breakout att…